Android app on Google Play

Baird Maintains an 'Outperform' on Achillion Pharmaceuticals (ACHN); Reassuring Clarification on '1625

April 23, 2012 2:22 PM EDT Send to a Friend
Get Alerts ACHN Hot Sheet
Price: $12.27 +6.05%

Rating Summary:
    13 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 14 | New: 52
Trade ACHN Now!
Join SI Premium – FREE
Baird maintains an 'Outperform' on Achillion Pharmaceuticals (NASDAQ: ACHN).

Analyst, Thomas Russo, said, "Incrementally positive following clarification of 4/21 update and conversation with management. We came away from EASL continuing to believe ACHN-8217's assets could remain relevant in HCV with success and, while certainly something to monitor, were not as surprised as maybe some others on safety/tolerability. Our concern had been whether there might be an emerging fundamental question on efficacy, but after the clarifying update we are reassured there. Management corrected its original sub-optimal handling of this, and the thesis is reinforced."

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $8.28 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Robert W Baird

Add Your Comment